The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases
Open accessAbstract
Patients with rare diseases are a major challenge for healthcare systems. These patients face three major obstacles: late diagnosis and misdiagnosis, lack of proper response to therapies, and absence of valid monitoring tools. We reviewed the relevant literature on first-generation artificial intelligence (AI) algorithms which were designed to improve the management of chronic diseases. The shortage of big data resources and the inability to provide patients with clinical value limit the use of these AI platforms by patients and physicians. In the present study, we reviewed the relevant literature on the obstacles encountered in the management of patients with rare diseases. Examples of currently available AI platforms are presented. The use of second-generation AI-based systems that are patient-tailored is presented. The system provides a means for early diagnosis and a method for improving the response to therapies based on clinically meaningful outcome parameters. The system may offer a patient-tailored monitoring tool that is based on parameters that are relevant to patients and caregivers and provides a clinically meaningful tool for follow-up. The system can provide an inclusive solution for patients with rare diseases and ensures adherence based on clinical responses. It has the potential advantage of not being dependent on large datasets and is a dynamic system that adapts to ongoing changes in patients' disease and response to therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patient monitoring: Continuous monitoring and realtime data analysis enable early detection of health issues and timely interventions, improving patient care and reducing healthcare costs [18].”
From Machine learning-based clinical decision support using laboratory data (2024) · cites this paper as [18]
Citations
Cites
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
From Triple to Quadruple Aim: Care of the Patient Requires Care of the Provider
Bodenheimer, T., & Sinsky, C. (2014) · The Annals of Family Medicine · doi:10.1370/afm.1713 · Cited by 3,462
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Key challenges for delivering clinical impact with artificial intelligence
Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. (2019) · BMC Medicine · doi:10.1186/s12916-019-1426-2 · Cited by 3,136 · cited 1×
“Concerns regarding unacceptable results, problems associated with data appropriateness, and the risk of bias are some of the challenges encountered by these first-generation systems [47].”
BackgroundArtificial intelligence in medicine
Hamet, P., & Tremblay, J. (2017) · Metabolism · doi:10.1016/j.metabol.2017.01.011 · Cited by 2,334
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Ruiter, A. M., Meilof, J. F., Somanje-Bolweg, R. R. J., van Gorsel, E., & Kalkers, N. F. (2017) · Case Reports in Neurology · doi:10.1159/000455942 · Cited by 1,762
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
What do we need to build explainable AI systems for the medical domain?
Holzinger, A., Biemann, C., Pattichis, C. S., & Kell, D. B. (2017) · arXiv · doi:10.48550/arxiv.1712.09923 · Cited by 636 · cited 1×
“AIs trained using big data are not suitable for many rare diseases where data are limited to a small number of patients [37, 38].”
BackgroundWeinreb, N. J., Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pastores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., et al. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01150-6 · Cited by 546
Research works printed but not linked: 2
- Dementia—caring, ethics, ethnical and economical aspects: a systematic review. SBU System Rev. 2008.
- Faviez C, Chen X, Garcelon N, Neuraz A, Knebelmann B, Salomon R, et al. Diagnosis support systems for rare diseases: a scoping review. Orphanet J Rare Dis. 2020;15:94. · DOI
Cited by
Mannuru, N. R., Shahriar, S., Teel, Z. A., Wang, T., Lund, B. D., Tijani, S., Pohboon, C. O., Agbaji, D., Alhassan, J., Galley, J., et al. (2025) · Information Development · doi:10.1177/02666669231200628 · Cited by 314
“With the continuous development of AI, it has been able to monitor health status and interpret changes in patient status, disease progression, treatment response, and environmental factors through a dynamic feedback loop, to improve treatment and care outcomes and reduce cost (Hurvitz et al., 2021).”
Artificial intelligence in rare disease diagnosis and treatment
Wojtara, M., Rana, E., Rahman, T., Khanna, P., & Singh, H. (2023) · Clinical and Translational Science · doi:10.1111/cts.13619 · Cited by 158
“4 These challenges in the diagnosis and treatment of rare diseases affect more than 350 million people worldwide and create a substantial economic burden on the healthcare system as well as result in poor patient outcomes.”
BackgroundThe Impact of Artificial Intelligence in the Odyssey of Rare Diseases
Visibelli, A., Roncaglia, B., Spiga, O., & Santucci, A. (2023) · Biomedicines · doi:10.3390/biomedicines11030887 · Cited by 141
Abdallah, S., Sharifa, M., Almadhoun, M. K. I. K., Khawar, M. M., Shaikh, U., Balabel, K. M., Saleh, I., Manzoor, A., Mandal, A. K., Ekomwereren, O., et al. (2023) · Cureus · doi:10.7759/cureus.46860 · Cited by 121
“Furthermore, the limited patient pool hampers the derivation of statistically significant parameters [22].”
BackgroundInfluentialPedro, A. R., Dias, M. B., Laranjo, L., Cunha, A. S., & Cordeiro, J. V. (2023) · PLOS ONE · doi:10.1371/journal.pone.0290613 · Cited by 74
Metadata
- Authors
- Hurvitz, N., Azmanov, H., Kesler, A., & Ilan, Y.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Corresponding author
- Ilan, Yaron
- Venue
- European Journal of Human Genetics
- Published
- 2021-07-19
- Volume
- 29
- Issue
- 10
- Pages
- 1485-1490
- ISSN
- 1018-4813 (ISSN-L)
- 1476-5438
- PMC
- PMC8484657
- OpenAlex
- W3184421451
- Cited by
- 106
- References
- 70
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 22 · 2023: 24 · 2022: 15 · 2021: 3
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- European Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Physical Sciences › Computer Science › Artificial Intelligence › Machine Learning in Healthcare
- Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
- Keywords
- rare diseases, artificial intelligence, early diagnosis, treatment response, clinical decision support, personalized medicine, chronic disease management, medication adherence
- MeSH terms
- Artificial Intelligence, Genetic Testing, Humans, Genetic Diseases, Inborn, Rare Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases. https://app.cochat.ai/papers/10.1038/s41431-021-00928-4
- The paper
- Hurvitz, N., Azmanov, H., Kesler, A., & Ilan, Y. (2021). Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases. European Journal of Human Genetics. https://doi.org/10.1038/s41431-021-00928-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.